---
title: "Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285376294.md"
description: "A patent has been granted for ATR-12, a genetically modified strain of S. epidermidis that produces a portion of human LEKTI protein. ATR-12 is under Phase 1b testing for treating Netherton syndrome. The location of this development is BRANFORD, Conn., as of May 6, 2026. Azitra, Inc. (NYSE...) is leading this innovative venture."
datetime: "2026-05-06T12:03:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285376294.md)
  - [en](https://longbridge.com/en/news/285376294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285376294.md)
---

# Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

A patent has been granted for ATR-12, a genetically modified strain of S. epidermidis that produces a portion of human LEKTI protein. ATR-12 is under Phase 1b testing for treating Netherton syndrome. The location of this development is BRANFORD, Conn., as of May 6, 2026. Azitra, Inc. (NYSE...) is leading this innovative venture.

### Related Stocks

- [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md)

## Related News & Research

- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [Natera says EXPAND trial of Fetal Focus single-gene NIPT tops 2,000 enrollees](https://longbridge.com/en/news/287052322.md)
- [Azitra reports Q1 2026 net loss $3.9M, cash $10.1M; advances ATR-12, ATR-04 trials](https://longbridge.com/en/news/286239732.md)
- [Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates | AZTR Stock News](https://longbridge.com/en/news/286262344.md)
- [4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy](https://longbridge.com/en/news/286655317.md)